These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18774412)

  • 1. Abacavir and increased risk of myocardial infarction.
    Post FA; Campbell LJ
    Lancet; 2008 Sep; 372(9641):803; author reply 804-5. PubMed ID: 18774412
    [No Abstract]   [Full Text] [Related]  

  • 2. Abacavir and the potential risk of myocardial infarction.
    Cutrell A; Brothers C; Yeo J; Hernandez J; Lapierre D
    Lancet; 2008 Apr; 371(9622):1413. PubMed ID: 18387668
    [No Abstract]   [Full Text] [Related]  

  • 3. Abacavir and increased risk of myocardial infarction.
    Goicoechea M; McCutchan A
    Lancet; 2008 Sep; 372(9641):803-4; author reply 804-5. PubMed ID: 18774413
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.
    Marcus JL; Neugebauer RS; Leyden WA; Chao CR; Xu L; Quesenberry CP; Klein DB; Towner WJ; Horberg MA; Silverberg MJ
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):413-9. PubMed ID: 26536316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 6. Abacavir and myocardial infarctions: the benefit of doubt?
    Behrens GM
    AIDS; 2011 Oct; 25(16):2043-5. PubMed ID: 21997489
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.
    Schafer JJ; Short WR; Squires KE
    Pharmacotherapy; 2010 Oct; 30(10):1072-83. PubMed ID: 20874044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warning against rechallenge with abacavir.
    AIDS Patient Care STDS; 1998 Mar; 12(3):229. PubMed ID: 11361938
    [No Abstract]   [Full Text] [Related]  

  • 9. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
    Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
    Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large lymphadenopathies complicating the abacavir hypersensitivity reaction.
    García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS
    AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059
    [No Abstract]   [Full Text] [Related]  

  • 11. Vertigo and abacavir.
    Fantry LE; Staecker H
    AIDS Patient Care STDS; 2002 Jan; 16(1):5-7. PubMed ID: 11839213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir-induced liver toxicity in an HIV-infected patient.
    Di Filippo E; Ripamonti D; Rizzi M
    AIDS; 2014 Feb; 28(4):613. PubMed ID: 24469001
    [No Abstract]   [Full Text] [Related]  

  • 13. Sweet's syndrome following abacavir therapy.
    Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
    J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
    [No Abstract]   [Full Text] [Related]  

  • 14. Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
    Kim C; Gupta SK; Green L; Taylor BM; Deuter-Reinhard M; Desta Z; Clauss M
    Antivir Ther; 2011; 16(8):1335-9. PubMed ID: 22155915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir and cardiovascular disease: A critical look at the data.
    Llibre JM; Hill A
    Antiviral Res; 2016 Aug; 132():116-21. PubMed ID: 27260856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 17. Abacavir and cardiovascular risk.
    Behrens GM; Reiss P
    Curr Opin Infect Dis; 2010 Feb; 23(1):9-14. PubMed ID: 19996748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.
    De Luca A; de Gaetano Donati K; Cozzi-Lepri A; Colafigli M; De Curtis A; Capobianchi MR; Antinori A; Giacometti A; Magnani G; Vullo V; Cauda R; Iacoviello L; d'Arminio Monforte A;
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):e98-101. PubMed ID: 22728753
    [No Abstract]   [Full Text] [Related]  

  • 19. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.
    Sax PE
    J Watch AIDS Clin Care; 2009 Oct; 21(10):81. PubMed ID: 20458812
    [No Abstract]   [Full Text] [Related]  

  • 20. Management protocol for abacavir-related hypersensitivity reaction.
    Clay PG; Rathbun RC; Slater LN
    Ann Pharmacother; 2000 Feb; 34(2):247-9. PubMed ID: 10676833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.